Press Releases

Press Contact

Anja Heuer

Corporate Communications, Immatics Biotechnologies GmbH

media@immatics.com

+49 89 540 415 606

Sidebar Social Links

Always up to date: Receive posts from us and our partners via our Twitter profile.

Find out more about Immatics on LinkedIn with our News, Events & Press Releases.

Press Releases

Year

Immatics Announces Board of Directors Additions Following Public Listing on NASDAQ

Houston, Texas and Tuebingen, Germany, July 09, 2020 (GLOBE NEWSWIRE) -- Houston, Texas and Tuebingen, Germany, July 9, 2020 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies,

Jul 09, 2020

Immatics - Board of Directors Press Release_FINAL

Immatics Announces Completion of Business Combination and Listing on NASDAQ

Houston, Texas and Tuebingen, Germany, July 02, 2020 (GLOBE NEWSWIRE) -- The business combination transaction with Arya Sciences Acquisition Corporation, a special purpose acquisition company sponsored by Perceptive Advisors, was completed on July 1, 2020 The combined company was renamed Immatics

Jul 02, 2020

PDF Version (DE)

PDF Version

Arya Sciences Acquisition Corp. Shareholders Approve Business Combination Transaction with Immatics

Arya Sciences Acquisition Corp. and Immatics Biotechnologies GmbH today announced that its respective shareholders approved the business combination announced on March 17, 2020. None of Arya’s shareholders redeemed their shares in connection with the ARYA shareholder approval.

Jun 29, 2020

PDF Version

Immatics Appoints Cedrik Britten as Chief Medical Officer

Former Head of Oncology Cell Therapy Research Unit at GSK to lead clinical development at Immatics.

Jun 04, 2020

PDF Version

Immatics Announces Business Combination with Arya Sciences Acquisition Corp., Creating a Publicly Listed Leader in TCR-based Immunotherapies

Upon successful completion of the business combination, Immatics will receive up to approximately $148 million of cash held within Arya’s trust account. Leading institutional investors commit $104 million of cash through a common stock private investment in public equity (“PIPE”).

Mar 17, 2020

PDF Version

PDF Version (DE)

Immatics and GSK Partner to Develop Novel Adoptive Cell Therapies

GSK to obtain access to two Immatics TCR-T programs, further advancing their commitment to the field of cell therapies. Immatics to receive €45 Million (~$50 Million) upfront payment with potential for additional milestone and royalty payments.

Feb 20, 2020

PDF Version

PDF Version (DE)

IR Toolkit

Print Page
Email Alerts
RSS Feeds
Contacts